Status:
NOT_YET_RECRUITING
Continuous Glucose Monitors (CGMs) and Readmission Rates
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
DexCom, Inc.
Conditions:
Diabetes (DM)
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Among the diffident groups of patients, those with chronic and severe medical conditions are more likely to be readmitted to the hospital. It is not surprising therefore that patients with diabetes ha...
Detailed Description
Utilizing CGM devices for patients with diabetes at hospital discharge can be a feasible and easily to implement intervention, improving glycemic control. Compared to Point of Care (POC) glucose testi...
Eligibility Criteria
Inclusion
- ≥18 years of age
- Patients with diabetes who are anticipated to be treated with any type of insulin after hospital discharge and with or without non-insulin medications (excluding those who are expected to be treated with correctional-sliding scale insulin regimens only
- Uncontrolled glycemic control, defined as hyperglycemia with HbA1c ≥8%
Exclusion
- Patients with diabetes who are anticipated to be treated with diet only, any combination of non-insulin antidiabetic drugs only, sliding scale correctional insulins (with or without non-insulin medications) after hospital discharge.
- Patients at the time of screening on insulin pumps or CGMs
- Pregnant patients
- Patients with extensive skin disease or allergies that preclude wearing the CGM sensor
- Patients without current access of (or who are unable to obtain) a smartphone device and internet
- Patients who have end-stage renal disease requiring dialysis
- Patients with significant psychiatric illness or any other condition which by investigator decision makes the subject incapable of understanding the objectives and potential consequences of the study
- taking hydroxyurea
- Employed by, or having immediate family members employed by Dexcom, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
Key Trial Info
Start Date :
November 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 17 2028
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07221812
Start Date
November 18 2025
End Date
November 17 2028
Last Update
November 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baltimore VA Medical Center
Baltimore, Maryland, United States, 21201